Profile data is unavailable for this security.
About the company
Alphamab Oncology is an investment holding company primarily engaged in the biopharmaceutical business. The Company is a full-industry chain enterprise specializing in research, development, manufacture, and commercialization of innovative tumor immunobiology macromolecular targeted drugs. The Company has bio-innovation drug development technology platform, including protein engineering platform, multi-functional antibody development platform and antibody screening platform. The Company operates its businesses in both domestic and overseas markets.
- Revenue in HKD (TTM)283.16m
- Net income in HKD-238.63m
- Incorporated2018
- Employees429.00
- LocationAlphamab OncologyNo. 175Fangzhou Road, Suzhou Industrial ParkSuzhou 215125ChinaCHN
- Phone+86 51 262850800
- Websitehttps://www.alphamabonc.com/en/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Laekna Inc | 0.00 | -327.06m | 2.55bn | 92.00 | -- | 3.41 | -- | -- | -0.9178 | -0.9178 | 0.00 | 1.92 | 0.00 | -- | -- | 0.00 | -31.46 | -- | -35.71 | -- | -- | -- | -- | -- | -- | -- | 0.0856 | -- | -- | -- | 52.81 | -- | -- | -- |
ImmuneOnco Biopharmaceuticls Shanghi Inc | 417.22k | -414.33m | 2.69bn | 150.00 | -- | 4.05 | -- | 6,447.96 | -1.15 | -1.15 | 0.0012 | 1.78 | -- | -- | -- | 2,877.35 | -- | -- | -- | -- | -- | -- | -99,307.43 | -- | -- | -- | 0.14 | -- | -28.25 | -- | 5.82 | -- | -- | -- |
Abbisko Cayman Ltd | 550.32m | -17.93m | 2.78bn | 275.00 | -- | 1.21 | 759.73 | 5.05 | -0.0304 | -0.0304 | 0.8473 | 3.37 | 0.2159 | -- | 65.75 | 2,133,021.00 | -0.7034 | -- | -0.733 | -- | 0.00 | -- | -3.26 | -- | -- | -- | 0.0142 | -- | -- | -- | 12.92 | -- | -- | -- |
CStone Pharmaceuticals | 505.23m | -157.49m | 2.80bn | 164.00 | -- | 5.41 | -- | 5.54 | -0.1236 | -0.1236 | 0.3963 | 0.403 | 0.2861 | 1.33 | 2.50 | 2,196,668.00 | -8.92 | -54.76 | -16.99 | -81.68 | 70.73 | -- | -31.17 | -301.62 | 1.45 | -- | 0.4171 | -- | -3.64 | -- | 59.32 | -- | 52.42 | -- |
CARsgen Therapeutics Holdings Ltd | 7.02m | -769.01m | 2.80bn | 477.00 | -- | 1.70 | -- | 399.15 | -1.38 | -1.38 | 0.0126 | 2.88 | 0.0027 | -- | 0.302 | 13,597.51 | -29.27 | -- | -32.86 | -- | 25.50 | -- | -10,960.25 | -- | 9.44 | -- | 0.1246 | -- | -- | -- | 16.19 | -- | -- | -- |
Biocytogen Pharmaceuticals Beijng Co Ltd | 885.98m | -269.83m | 3.91bn | 1.04k | -- | 4.78 | -- | 4.41 | -0.6775 | -0.6775 | 2.22 | 2.05 | 0.3109 | 23.64 | 5.36 | 831,122.00 | -9.47 | -- | -12.44 | -- | 71.97 | -- | -30.46 | -- | 1.33 | -4.18 | 0.436 | -- | 34.28 | -- | 36.38 | -- | -- | -- |
Alphamab Oncology | 283.16m | -238.63m | 4.78bn | 429.00 | -- | 2.66 | -- | 16.88 | -0.2479 | -0.2479 | 0.2941 | 1.87 | 0.1145 | 0.8256 | 13.94 | 650,953.70 | -9.65 | -18.72 | -11.16 | -21.94 | 79.33 | -- | -84.27 | -415.55 | 4.42 | -- | 0.167 | -- | 31.12 | -- | 35.35 | -- | -13.12 | -- |
Qyuns Therapeutics Co Ltd | 49.71m | -466.80m | 5.20bn | 325.00 | -- | 11.78 | -- | 104.53 | -1.99 | -1.99 | 0.2256 | 1.99 | -- | -- | -- | 150,183.40 | -- | -- | -- | -- | 84.05 | -- | -976.77 | -- | 1.83 | -28.07 | 0.5795 | -- | -- | -- | -70.28 | -- | -- | -- |
Data as of Oct 08 2024. Currency figures normalised to Alphamab Oncology's reporting currency: Hong Kong Dollar HKD
Holder | Shares | % Held |
---|---|---|
The Vanguard Group, Inc.as of 04 Jul 2024 | 23.84m | 2.47% |
Zhong Ou Asset Management Co., Ltdas of 31 Dec 2023 | 16.02m | 1.66% |
GF Fund Management Co., Ltd.as of 31 Dec 2023 | 12.24m | 1.27% |
First Seafront Fund Management Co., Ltd.as of 31 Dec 2023 | 8.52m | 0.88% |
Bosera Asset Management Co., Ltd.as of 31 Dec 2023 | 7.75m | 0.80% |
BlackRock Fund Advisorsas of 04 Jul 2024 | 6.52m | 0.68% |
China Asset Management Co., Ltd.as of 31 Dec 2023 | 2.19m | 0.23% |
BlackRock Advisors (UK) Ltd.as of 04 Jul 2024 | 1.72m | 0.18% |
Invesco Great Wall Fund Management Co. Ltd. (Invt Mgmt)as of 31 Dec 2023 | 1.18m | 0.12% |
E Fund Asset Management Co. Ltd.as of 31 Dec 2023 | 968.00k | 0.10% |
More ▼
Data from 31 Dec 2023 - 06 Aug 2024Source: FactSet Research Systems Inc.